-
-
-
-
-
-
-
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress
-
-
-
-
-
-
-
Cullinan Therapeutics (CGEM) Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978
-
-
-
-
67,771 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

